Genovis AB (OSTO:GENO) Cyclically Adjusted Revenue per Share: kr1.49 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:GENO Genovis AB OSTO:GENO
96 GF Score
Price kr19.34
GF Value kr26.51
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genovis AB Cyclically Adjusted Revenue per Share?

Genovis AB OSTO:GENO +1.26% 96 Cyclically Adjusted Revenue per Share is kr1.49 as of Jun. 2026. GuruFocus rates OSTO:GENO with a GF Score™ of 96/100 and a GF Value™ of kr26.51 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genovis AB's adjusted revenue per share for the three months ended in Jun. 2026 was kr0.516. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr1.49 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Genovis AB's average Cyclically Adjusted Revenue Growth Rate was 12.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 17.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 21.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genovis AB was 26.40% per year. The lowest was 16.80% per year. And the median was 21.50% per year.

As of today (2026-08-06), Genovis AB's current stock price is kr19.34. Genovis AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr1.49. Genovis AB's Cyclically Adjusted PS Ratio of today is 12.98.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genovis AB was 135.83. The lowest was 9.45. And the median was 45.94.


Genovis AB  (OSTO:GENO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genovis AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=19.34/1.49
=12.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genovis AB was 135.83. The lowest was 9.45. And the median was 45.94.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genovis AB Cyclically Adjusted Revenue per Share Related Terms


Genovis AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Genovis AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovis AB Cyclically Adjusted Revenue per Share Chart

Genovis AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.67 0.86 1.09 1.26 1.40

Genovis AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 1.35 1.40 1.44 1.49

OSTO:GENO vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Genovis AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genovis AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genovis AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genovis AB's Cyclically Adjusted PS Ratio falls into.


OSTO:GENO
96GF Score
Genovis AB OSTO:GENO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genovis AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genovis AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.516/134.6100*134.6100
=0.516

Current CPI (Jun. 2026) = 134.6100.

Genovis AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.084 101.138 0.112
201612 0.100 102.022 0.132
201703 0.087 102.022 0.115
201706 0.099 102.752 0.130
201709 0.088 103.279 0.115
201712 0.116 103.793 0.150
201803 0.104 103.962 0.135
201806 0.140 104.875 0.180
201809 0.146 105.679 0.186
201812 0.167 105.912 0.212
201903 0.189 105.886 0.240
201906 0.182 106.742 0.230
201909 0.385 107.214 0.483
201912 0.203 107.766 0.254
202003 0.175 106.563 0.221
202006 0.237 107.498 0.297
202009 0.217 107.635 0.271
202012 0.303 108.296 0.377
202103 0.240 108.360 0.298
202106 0.298 108.928 0.368
202109 0.240 110.338 0.293
202112 0.642 112.486 0.768
202203 0.498 114.825 0.584
202206 0.322 118.384 0.366
202209 0.351 122.296 0.386
202212 0.393 126.365 0.419
202303 1.089 127.042 1.154
202306 0.450 129.407 0.468
202309 0.461 130.224 0.477
202312 0.417 131.912 0.426
202403 0.612 132.205 0.623
202406 0.450 132.716 0.456
202409 0.502 132.304 0.511
202412 0.427 132.987 0.432
202503 0.493 132.825 0.500
202506 0.441 133.699 0.444
202509 0.417 133.480 0.421
202512 0.609 133.390 0.615
202603 0.507 133.560 0.511
202606 0.516 134.610 0.516

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr1.49 mean?
Genovis AB (OSTO:GENO) has a Cyclically Adjusted Revenue per Share of kr1.49 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genovis AB and its competitors.
Is Genovis AB's Cyclically Adjusted Revenue per Share too high?
Genovis AB's current Cyclically Adjusted Revenue per Share is kr1.49. Overall, Genovis AB has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Genovis AB's Cyclically Adjusted Revenue per Share of kr1.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genovis AB and its competitors. Genovis AB's current Cyclically Adjusted Revenue per Share is kr1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (OSTO:GENO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr26.51, compared to a current price of kr19.34 — trading 27% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr1.49. Genovis AB's overall GF Score™ is 96/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Genovis AB (OSTO:GENO), the current Cyclically Adjusted Revenue per Share is kr1.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovis AB (OSTO:GENO) Overvalued in 2026?

Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued. The current stock price of kr19.34 is trading 27% below its estimated GF Value™ of kr26.51. GuruFocus considers Genovis AB to be Modestly Undervalued.

Key valuation signals for OSTO:GENO:

  • Cyclically Adjusted Revenue per Share: kr1.49
  • GF Value™: kr26.51 vs. price of kr19.34 (27% below fair value)
  • GF Score™: 96/100 with 2 warning signs

No single metric tells the full story. See the OSTO:GENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genovis AB Business Description

Address Kavlinge, Box 4, Lund, SWE, SE-24421
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
96GF Score

Get the complete analysis for OSTO:GENO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr19.34
Price
kr26.51
GF Value